Sun Pharmaceutical Industries Limited, a leader in the pharmaceutical industry, is dedicated to advancing patient care in areas such as psoriasis, alopecia areata, and acne. At the 2026 AAD Annual Meeting held in Denver, Colorado, Sun Pharma presented 14 abstracts, highlighting its commitment to dermatology and immunology.

Among the key developments, ILUMYA, which targets moderate-to-severe plaque psoriasis and nail psoriasis, continues to show promise in improving patient outcomes. Additionally, LEQSELVI is being utilized for the treatment of severe alopecia areata, while WINLEVI is indicated for acne vulgaris and is often used in combination therapies.

However, not all news was positive; the Phase II FLASH study for Fibromun did not meet its primary endpoint for progression-free survival (PFS). This outcome raises questions about the future direction of this treatment.

On a more encouraging note, Nidlegy achieved complete pathological responses in 52.6% of patients in the Phase II ‘Duncan’ study, demonstrating significant efficacy. Furthermore, the GLIOSTELLA study in late-line glioblastoma has completed enrollment in the U.S., marking a critical step forward in cancer research.

Following the withdrawal of a prior Marketing Authorization Application in 2025, Sun Pharma is preparing a new submission for Nidlegy, reflecting its ongoing commitment to bringing innovative therapies to market.

Dr. Ahmad Naim commented on the presentations, stating, “The data we are presenting at AAD underscore our commitment to advancing dermatology and immunology through meaningful science – spanning not only clinical efficacy and safety, but also how these therapies perform over time and in real-world practice.” This statement reinforces the company’s focus on long-term patient care.

As the industry watches closely, observers anticipate further developments from Sun Pharma, particularly regarding the outcomes of ongoing studies and the potential impact of new submissions on the market.

Details remain unconfirmed regarding the future of Fibromun, but the company’s proactive approach suggests a determination to refine its strategies and improve patient outcomes across its product range.

The post Sun Pharma Advances Dermatology Research at AAD Annual Meeting appeared first on berightnews.

On March 4, 2026, South Korea’s stock market experienced its steepest fall in history, with the KOSPI index plummeting by 12.06 percent. This unprecedented drop has raised alarms about the economic stability of the nation, particularly in light of the ongoing US-Iran war, which has had significant repercussions across global markets.

Causes of the Market Meltdown

The market meltdown is the latest example of economic shockwaves unleashed by the conflict in the Middle East. The KOSPI had already seen a troubling 7.2 percent decline on March 3, 2026, marking the worst two-day streak in decades. As losses exceeded the 8 percent threshold, South Korean financial authorities activated a 20-minute circuit breaker to prevent further panic selling.

Impact on Key Sectors

Shipping and logistics firms were among the hardest hit, suffering steep losses due to the effective halt of traffic through the Strait of Hormuz, a vital maritime route for global oil shipments. Companies like HMM and KSS Line faced significant challenges as the geopolitical tensions disrupted their operations.

Investment in Healthcare and Biotechnology

Amid this turmoil, there is a contrasting development in South Korea’s healthcare and biotechnology sector. Roche has announced plans to invest approximately 710 billion won (around $481 million) in the country over the next five years. This investment aims to bolster South Korea’s biopharma ecosystem by conducting global clinical trials and expanding research collaborations with local biotech firms.

Strengthening Clinical Trial Capabilities

Roche’s partnership is expected to enhance clinical trial capabilities in South Korea, which has already been recognized for its cost-effective clinical trials—estimated to be 30-40 percent cheaper than those in the US or Japan. In 2024, global pharmaceutical companies invested about 1.04 trillion won in Korean clinical research, reflecting a 74 percent increase from 2020. This trend underscores South Korea’s growing significance in the global healthcare landscape.

Seoul had ranked first globally for clinical trial activity for seven consecutive years starting in 2017 before slipping to second place in 2024. The recent investment from Roche is seen as a strategic move to regain that top position and further develop the local biohealth industry.

Future Developments and Uncertainties

As South Korea navigates these economic challenges, the long-term effects of the US-Iran conflict on its markets remain uncertain. The potential for further market volatility looms large, and while investments in healthcare may provide some stability, the overall economic outlook is still precarious. Details remain unconfirmed regarding the full extent of the impact on various sectors as the situation evolves.

The post South Korea Faces Historic Stock Market Plunge Amid US-Iran War appeared first on berightnews.